Fundraising Fox

Myricx Bio

London, GB · 38 employees on LinkedIn · 4 known investors

Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.

BiotechMedical Devices

Investors · 4

Brandon Capital Partners
Novo HoldingsCopenhagen · $1.1M – $54M
Sofinnova PartnersParis · $540K – $27M
AbingworthreportedLondon · $15M – $30M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFNtechfundingnews.com · Jul 2026Imperial cancer therapy spinout Myricx Bio agrees to be acquired by Novartis | Imperial News | Imperial College Londonimperial.ac.uk · Jul 2026Myricx Bio Awarded Cancer Research Horizons Start-Up Achievement Recognition Award for 2025 - Brandon Capitalbrandoncapital.vc · Aug 2025Myricx Bio Raises £90M in Series A Fundingfinsmes.com · Jul 2024Myricx Bio raises $114 million for ADCs with novel payloadcen.acs.org · Jul 2024

Frequently asked questions

What does Myricx Bio do?
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.
Who are Myricx Bio's investors?
Myricx Bio's investors include Brandon Capital Partners, Novo Holdings, Sofinnova Partners, Abingworth.
Where is Myricx Bio headquartered?
Myricx Bio is headquartered in London, GB.